GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

ORLANDO, Fla.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled medical devices and digital solutions in Booth 2500 at the Health Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition in Orlando, FL from March 11-15, 2024. In the U.S., clinicians spend nearly twice as much time working with electronic health records as working with patients.i This challenge is only increasing a.

GE HealthCare to Spotlight Industry-Leading AI-Enabled Portfolio and Digital Solutions at HIMSS 2024

Newly independent GE Healthcare thinks it can significantly grow its profit margin in the coming years. An impressive pipeline of new product introductions is driving sales growth and margin expansion.

Here's Why This Magnificent Healthcare Stock Is Soaring in 2024

GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.

GE HealthCare's (GEHC) New Launch to Enhance Precision Care

A combination of growth prospects in AI and emerging treatment technologies like theranostics supports growth at this healthcare company. Revenue growth and margin expansion are on the cards for GE HealthCare Technologies in the coming years.

Why GE HealthCare Technologies Stock Soared More Than 24% in February

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its latest innovation in ultrasound with the launch of its next-level LOGIQ ultrasound portfolio—including the new LOGIQ Totus—highlighting the company's progress in advancing precision care. LOGIQ, is a trusted companion in general ultrasound imaging and has supported clinicians in delivering high-quality, patient-driven innovation for more than 30 years. The elevated LOGIQ portfolio innovative new features and advanced art.

GE HealthCare Showcases Precision Care with Launch of Elevated LOGIQ Ultrasound System Portfolio at European Congress of Radiology 2024

GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.

GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care

Collaboration supports the patient journey across the care continuum and eases transitions and care from the hospital to home CHICAGO and BOSTON , Feb. 26, 2024 /PRNewswire/ -- GE HealthCare (Nasdaq: GEHC) and Biofourmis have announced a strategic collaboration aimed at enhancing continuity of care by enabling safe, effective, and accessible care in the home to support the patient journey beyond the hospital setting. The collaboration leverages the combined expertise of two market leaders to scale and deliver innovative care-at-home solutions.

GE HealthCare and Biofourmis Collaborate to Extend Patient Monitoring Outside the Hospital with Virtual Care-at-Home Solutions

GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.

GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why GE HealthCare Technologies (GEHC) is a Strong Momentum Stock

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a collaboration with OSF HealthCare, an integrated health system caring for patients throughout Illinois and Michigan, and Pointcore, Inc., a healthcare management and non-clinical shared services company, to help increase clinical and operational efficiencies, standardize care delivery models and improve patient outcomes across OSF HealthCare. This alliance will leverage GE HealthCare's expertise and innovative technology a.

Serving Patients and Communities Through Comprehensive Care Solutions: OSF HealthCare, Pointcore, Inc. and GE HealthCare Enter Strategic Care Alliance

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced secondary underwritten public offering (the “Offering”) of 13,000,000 shares of its common stock (the “GEHC Shares”) at a public offering price of $82.25 per share ($80.605 per share, net of underwriting discount). GE HealthCare is not selling any shares of common stock and will not receive any proceeds from the sale of the GEHC Shar.

GE HealthCare Technologies Inc. Prices Secondary Offering of 13,000,000 Shares

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Why GE HealthCare Technologies (GEHC) is a Top Stock for the Long-Term

GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.

GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities, today announced a three-year collaboration to deliver excellence in patient care by providing access to innovative technologies from GE HealthCare and the infrastructure and resources from MedQuest that are needed to optimize.

GE HealthCare and MedQuest Associates Collaborate to Provide Innovative Medical Device Technology and Digital Tools for Outpatient Imaging Centers

GE HealthCare's (GEHC) fourth-quarter results benefit from continued demand for imaging, patient care and pharmaceutical diagnostic solutions. Sales gain from improved pricing.

GE HealthCare (GEHC) Q4 Earnings Beat, Volume & Price Improve

GE HealthCare Technologies Inc. (GEHC) Q4 2023 Earnings Call Transcript

CHICAGO--(BUSINESS WIRE)--GE HealthCare (GEHC), a leading global precision care innovator, today reported financial results for the fourth quarter ended December 31, 2023.

INSERTING and REPLACING GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results

GE Healthcare Technologies Inc (NASDAQ:GEHC) shares gained more than 12% on Tuesday morning after the GE spinoff posted strong results for its first full year as a standalone company. For 4Q, revenue grew 5% over the year-ago quarter to $5.2 billion, ahead of estimates of $5.1 billion.

GE HealthCare Technologies stock surges on 4Q earnings beat

While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GE HealthCare (GEHC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.31 per share a year ago.

GE HealthCare Technologies (GEHC) Q4 Earnings and Revenues Surpass Estimates

GE HealthCare forecast 2024 profit largely above Wall Street expectations and beat fourth-quarter profit estimates on strong demand for its imaging devices, sending the company's shares up 2% before the bell on Tuesday.

GE HealthCare forecasts 2024 profit largely above estimates

GE HealthCare Technologies Inc.'s stock GEHC, -0.68% rose 0.9% early Tuesday, after the company posted better-than-expected profit and revenue for the fourth quarter, offsetting soft guidance for 2024. GE HealthCare, which was spun out of General Electric Co. in January of 2023 and houses its medical device business, posted net income of $403 million, or 88 cents a share, for the quarter, down from $554 million, or $1.21 a share, in the year-earlier period.

GE Healthcare's Q4 profit and revenue top estimates, offsetting soft EPS guidance

GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.

GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for Novii™+ Wireless Patch Solution. The antepartum and intrapartum maternal and fetal monitor noninvasively measures and displays fetal heart rate, maternal heart rate and uterine activity, so care teams can have a real-time view of patient data. Through its belt-free and wireless design, Novii+ enables mobility and freedom for mother.

Novii+ Wireless Maternal and Fetal Monitoring Solution Cleared by the FDA for Monitoring Approximately 95% of All Eligible Births in the United States1

News for GE HealthCare Technologies Inc Stock (GEHC)